Y-mAbs Therapeutics, Inc. announced the presentation of preclinical and translational pharmacokinetics (PK) data for their CD38-SADA bispecific fusion protein at the 2025 AACR Annual Meeting in ...

From its inception in 2015, the company has been focused exclusively on discovering and developing innovative biologics, including monoclonal antibodies (mAbs), fusion proteins and bispecific ...

Y-mAbs Therapeutics (YMAB) announced the presentation of preclinical and translational pharmacokinetics, PK, data of CD38-SADA in a poster at ...

By strengthening the offering of protein A resins in clinical production, Cytiva stated n continues to build on global representation and support the mAb industry with innovative, reliable, and ...

The current clinical pipeline of biologic drugs includes 240 mAbs and 120 proteins in various other categories, including alternative scaffolds, fusion proteins and recombinant versions of ...

Join us for this webinar to learn how Roche CustomBiotech FcRn affinity columns work, and how they can be easily implemented into your development workflow to support the design of new antibodies, mAb ...

About IBI363 (First-in-class PD-1/IL-2α-bias bispecific antibody fusion protein) IBI363 is a first-in-class drug candidate independently developed by Innovent Biologics. It is a PD-1/IL-2 ...